MBX Biosciences, a clinical-stage biopharmaceutical company specializing in precision peptide therapies, announced that its CEO Steve Hoerter and CMO Dr. Sam Azoulay will present at three upcoming investor conferences in November 2026: Guggenheim Healthcare Innovation, UBS Global Biopharma, and Jefferies Global Healthcare. These presentations include fireside chats and one-on-one meetings, offering insights into the company's pipeline, which includes treatments for endocrine and metabolic disorders such as chronic hypoparathyroidism and obesity. The events will be webcast live and archived for 90 days, providing investors access to the latest company updates and strategic direction.
MBX Biosciences' participation in November investor conferences is presented here with a snapshot of the health sector on Pluang as of Oct 13, 2026 18:43 WIB: Out of 128 priced health-sector US stocks, 76 rose and 46 fell. InMode Ltd (INMD) at USD 14.55 gained 1.75% with 100% buy order activity, contrasting Abbott Laboratories (ABT) at USD 103.60 which also rose 1.75% but saw 85% sell orders. Johnson & Johnson (JNJ) traded at USD 259.26 declined by 1.69% with 84% sell orders, showing varied investor sentiment and hold times ranging from 29 to 129 days.
Existing-home sales in the U.S. increased by 1.5% month-over-month in September but declined 2.2% compared to the previous year, according to the National Association of Realtors. Sales rose in the South and West regions but fell in the Northeast and...
Columbus Marketing Experts, a digital marketing agency in Hilliard, Ohio, is expanding its local SEO services across Columbus to help service businesses improve their visibility on Google Search and Google Maps. The expansion aims to enhance local di...
Schrödinger's stock fell 5.02% to $25.91 despite co-founding Tectora, a new biopharma venture with $55 million funding targeting immune and inflammatory treatments. The company, known for its molecular modeling software, holds a market value of about...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Nvidia CEO Jensen Huang has reaffirmed his forecast that global spending on AI infrastructure will grow significantly, reaching between $3 trillion and $4 trillion by 2030. This projection highlights the massive potential and ongoing investment in AI...
